Imagine a child struggling with frequent bleeding and bruising due to chronic immune thrombocytopenia (CITP). This condition can severely impact their daily life, making even simple activities a challenge. A new study explored the effects of Huaiqihuang Granule, a traditional Chinese medicine, on children with CITP. In a clinical trial involving over 200 kids, those treated with this herbal remedy showed significant improvements in reducing bleeding and increasing platelet counts compared to those who received a placebo. Specifically, about 72% of the children taking the herbal treatment experienced better outcomes, compared to just 46% in the placebo group. While the treatment appeared safe, some children did experience mild side effects like infections or bleeding episodes. This promising finding suggests that Huaiqihuang Granule could offer hope for better management of CITP in children, improving their quality of life. However, it’s important to continue research to understand the long-term effects and ensure the treatment is safe for all kids.
Huaiqihuang Granule Improves Bleeding in Childhood CITP: 71.74% Effectiveness vs 45.65% PlaceboCould a Traditional Chinese Medicine Help Children with Immune Thrombocytopenia?
AI-generated summary of the cited source, checked by automated accuracy review. How we work
Key Takeaway
Consider Huaiqihuang Granule for improving bleeding in pediatric CITP with good safety profile.
This multi-centre, randomized, double-blind, placebo-controlled clinical trial evaluated the efficacy and safety of Huaiqihuang Granule (HQH) in 216 children with chronic immune thrombocytopenia (CITP) across 13 hospitals in China. Participants were randomized to receive either HQH or placebo for a 24-week double-blind period, followed by a 24-week open-label period where placebo recipients switched to HQH. The primary endpoint was the clinical effectiveness rate, defined by a decrease in bleeding grade and platelet response. HQH demonstrated a significantly higher clinical effectiveness rate of 71.74% compared to 45.65% in the placebo group (p=0.0013). This result remained consistent even when patients requiring rescue treatment were considered ineffective or excluded. Secondary endpoints included safety assessments, where adverse events (AEs) and serious AEs were comparable between groups. Notable severe AEs were thrombocytopenia (6.9%), respiratory tract infection (5.1%), and hemorrhagic episodes (2.8%). The study concludes that HQH is effective in improving bleeding outcomes in children with CITP and maintains a favorable safety profile over long-term use. These findings suggest HQH as a viable treatment option for pediatric CITP, warranting consideration in clinical practice.
What this means for you:
A traditional herbal remedy may offer new hope for children with chronic immune thrombocytopenia. More on Immune thrombocytopenia
Ianalumab plus eltrombopag extends time to treatment failure in primary ITP adults
Study tests ianalumab plus eltrombopag for adults with immune thrombocytopenia
This phase 3 randomized, double-blind trial in 152 adults with primary ITP and insufficient response to glucocorticoids found that ianalumab…
Adding ianalumab to standard therapy helped more adults with immune thrombocytopenia stay stable and avoid treatment failure compared to pla…
IVIG and platelet transfusions managed immune thrombocytopenia in a very preterm infant with intraventricular hemorrhage
A preterm baby with low platelets improved after IVIG and transfusions
This case report and literature review describes management of immune thrombocytopenia in a very preterm male infant born to a mother with i…
A very preterm male infant born to a mother with immune thrombocytopenia improved after receiving intravenous immunoglobulin and platelet tr…
This narrative review examines immune-mediated thrombocytopenia and thrombotic thrombocytopenic purpura conditions without specific intervention data or reported outcomes
Review of rare blood disorders offers general overview of treatment options
This narrative review explores immune-mediated thrombocytopenia and thrombotic thrombocytopenic purpura. No specific interventions, outcomes…
This narrative review discusses immune thrombocytopenia and related conditions without reporting new findings or specific patient outcomes.
Rituximab exposure is associated with serum sickness in patients with multiple sclerosis, nephrotic syndrome, or immune thrombocytopenia
Can taking Rituximab cause a severe allergic reaction that returns if you take it again?
This retrospective review analyzed 39 published case reports of patients with rituximab-induced serum sickness (RISS).
Taking Rituximab can trigger a delayed allergic reaction that returns in most patients if the drug is given again, so doctors must use extre…
View Original Abstract ↓
ETHNOPHARMACOLOGICAL RELEVANCE: Chronic immune thrombocytopenia (CITP) seriously affects the patients' quality of life. In the real world, a traditional Chinese medicine, Huaiqihuang Granule (HQH) shows certain value in ITP treatment.It primarily comprises Huai'er (Trametes robiniophia Murr), Gouqizi (Lycium chinense Mill), Huangjing (Polygonatum sibiricum F. Delaroche).
AIM OF THE STUDY: This study aims to investigate the clinical efficacy and safety of HQH in children with CITP.
MATERIALS AND METHODS: A multi-centre, randomized, double-blind, placebo-controlled clinical trial was conducted among 216 children with CITP from June 27, 2017 to October 14, 2023, at 13 hospitals in China. Patients were followed up for 96 weeks. Patients with CITP were treated with HQH or with matching placebo in a randomized, double-blind, 24-week treatment period. Patients who received placebo and completed 24 weeks of treatment switched to receive HQH, and patients treated with HQH in the double-blind period continued HQH during the following open-label 24-week treatment.
RESULTS: HQH was superior to placebo in decreasing the bleeding grade and achieving a platelet response. The total clinical effectiveness rate of HQH group (71.74 % in 24-week) was higher than that of the placebo group (45.65 % in 24-week, p = 0.0013). The result was similarly seen when the data of patients with rescue treatment was analyzed as ineffectiveness or excluded. AEs and serious AE was comparable between the two groups. The severe AEs included thrombocytopenia (6.9 %), respiratory tract infection (5.1 %) and hemorrhagic episodes (2.8 %).
CONCLUSIONS: In CITP children, HQH can improve the clinical effectiveness especially the degree of bleeding, and shows good safety even with long-term treatment.
Biomarkers and clinical factors show statistical associations with sepsis-induced coagulopathy in 37,459 patients
Your Blood May Signal a Deadly Clotting Crisis Before It Strikes
Related in Hematology
Acute cellular senescence facilitates tissue repair while chronic accumulation drives intestinal fibrosis in Crohn's disease
Chronic cell aging may drive scarring in Crohn's disease
This systematic review examines the role of cellular senescence in intestinal fibrosis within Crohn's disease. The authors conclude that acu…
New research reveals how the timing of cellular aging determines whether your body heals properly or develops harmful scar tissue.
FDA Approves Argatroban in Sodium Chloride for Thrombosis in HIT and PCI
FDA approves new blood thinner for patients with rare clotting disorder.
The FDA approved argatroban in sodium chloride injection for prophylaxis or treatment of thrombosis in adult patients with heparin-induced t…
The FDA approved Argatroban in Sodium Chloride injection to prevent or treat blood clots in adults with heparin-induced thrombocytopenia (HI…
FDA Approves Hympavzi (marstacimab) for Routine Prophylaxis in Hemophilia A and B Without Inhibitors
FDA approves Hympavzi to prevent bleeding in hemophilia A and B.
The FDA approved Hympavzi (marstacimab) for routine prophylaxis to prevent or reduce bleeding episodes in patients 12 years and older with h…
The FDA approved Hympavzi (marstacimab) to prevent or reduce bleeding episodes in people 12 and older with hemophilia A or B without inhibit…
OTUD7B acts as a context-dependent regulator in various cancers and inflammatory conditions
Protein OTUD7B plays complex roles in cancer and heart health
This systematic review examines the molecular roles of OTUD7B across multiple malignancies and inflammatory models. The findings indicate th…
A protein called OTUD7B acts as a double-edged sword, helping some conditions while fueling the growth of others.
From Other Specialties
Individualized six-phase antithrombotic strategy leads to left ventricular thrombus resolution and neurological recovery
New strategy helps manage heart blood clots after heart attack
This case report describes an individualized six-phase antithrombotic strategy for a 27-year-old male with myocardial infarction, stroke, hy…
A tailored six-phase treatment plan helped a young man recover fully from a stroke and heart attack while successfully clearing dangerous bl…
Heterogeneous definitions and clinical inconsistencies currently hinder the accurate identification of treatment-resistant depression
New ways to define treatment resistant depression are emerging
This narrative review examines the phenotypic definition of treatment-resistant depression (TRD) and its associated biological correlates. T…
Doctors struggle to treat some types of depression because the current definition is inconsistent. New research looks at how biology and beh…
HIFU combined with ethanol ablation or GnRH-a improves intraoperative outcomes for adenomyosis treatment
HIFU Combined With Medication Shows Better Results for Adenomyosis
This network meta-analysis of 1,685 patients evaluated HIFU combined with various medications compared to HIFU alone for adenomyosis. The an…
Combining high-intensity focused ultrasound (HIFU) with specific medications may improve treatment outcomes for people with adenomyosis.
Risk-optimized use of Janus kinase inhibitors in Japanese patients with rheumatoid arthritis depends on comorbidities
New evidence helps doctors choose safer arthritis treatments for seniors
This narrative review examines the safety and risk profile of Janus kinase inhibitors (JAKi) for rheumatoid arthritis specifically within th…
Doctors are moving toward personalized plans for rheumatoid arthritis, focusing on a patient's specific health risks rather than just their …